EIKN

Eikon Therapeutics Inc

10.73

Sep 09 • 3:59 PM ET +0.02 (0.19%)

10.73

Aftermarket • 4:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: IDYA RCUS TNGX CGON CRNX BMRN INCY KYMR RYTM KRYS

| Held by: VTI VXF VTWO SCHA SBIO OMFS SCHB VTWG TINY RSSL

Scroll to Statements

Index	RUT
Market Cap	581.19M
Enterprise Value	301.83M
Income	-
Sales	-
Book/sh	8.62
Cash/sh	9.81
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Feb 05, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.25
P/C	1.09
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.89
Current Ratio	9.89
Debt/Eq	0.54
LT Debt/Eq	0.52
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-7.08
EPS next Q	-1.70
EPS this Y	93.86%
EPS next Y	-0.03%
EPS next 5Y	61.99%
EPS past 3/5Y	-13.35% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-10.51%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-2.84% -

Insider Own	53.25%
Insider Trans	0.31%
Inst Own	42.80%
Inst Trans	6.22%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.44%
SMA50	1.60%
SMA200	-3.45%
Trades

Shs Outstand	54.15M
Shs Float	25.32M
Short Float	16.51%
Short Ratio	10.06
Short Interest	4.18M
52W High	17.40 -38.33%
52W Low	7.90 35.82%
Volatility	6.56% 9.33%
ATR (14)	0.89
RSI (14)	49.43
Beta	-
Rel Volume	1.81
Avg Volume	415.53K
Volume	751,606

Perf Week	-1.38%
Perf Month	10.28%
Perf Quarter	22.35%
Perf Half Y	-23.47%
Perf YTD	-37.07%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.67
Target Price	24.60
Prev Close	10.71
Price	10.73
Change %	0.19%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-02-26	Initiated	Morgan Stanley	Overweight	$32
Mar-02-26	Initiated	Mizuho	Outperform	$26
Mar-02-26	Initiated	JP Morgan	Overweight	$29
Mar-02-26	Initiated	Cantor Fitzgerald	Overweight
Mar-02-26	Initiated	BofA Securities	Buy	$34
Feb-26-26	Initiated	Wedbush	Underperform	$7

Sep-03-26 07:30AM	Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer (GlobeNewswire)
Aug-26-26 07:30AM	Eikon Therapeutics to Participate in Investor Conferences in September 2026 (GlobeNewswire)
Aug-18-26 04:15PM	Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald (GlobeNewswire) +11.27%
Aug-13-26 04:02PM	Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates (GlobeNewswire) +6.97%
Aug-11-26 07:30AM	Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma (GlobeNewswire) +5.14%
07:30AM	Loading…
Aug-10-26 07:30AM	Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board (GlobeNewswire)
Jul-27-26 07:30AM	Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer (GlobeNewswire) +11.01%
Jul-20-26 08:00AM	Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress (GlobeNewswire)
Jun-25-26 04:15PM	Eikon Therapeutics to Join the Russell 3000 Index (GlobeNewswire) +16.24%
Jun-08-26 08:00AM	Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors (GlobeNewswire)
May-30-26 02:30PM	Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology (GlobeNewswire)
May-21-26 05:05PM	Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (GlobeNewswire)
May-11-26 04:01PM	Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates (GlobeNewswire) +15.88%
Mar-30-26 07:48AM	Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire)
Feb-26-26 09:42AM	Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls (The Fly) -8.39%
12:02PM	Loading…
Feb-24-26 12:02PM	Medtronic Diabetes Unit MiniMed Seeks $784 Million in US IPO (Bloomberg)
Feb-09-26 08:30AM	Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead (Benzinga)
Feb-06-26 04:18PM	Jennifer Garner's Once Upon a Farm Rises Nearly 20% To Wrap Up Busy Week for IPOs (Barrons.com)
Feb-05-26 07:23PM	This Mobile App Marketing Firm Is Holding Off an IPO for Now (Barrons.com)
Feb-04-26 07:59PM	Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Eikon Therapeutics is a biopharmaceutical company. It engages in the development of medicines for unmet medical needs. The company was founded in 2019 and is headquartered in Millbrae, CA.

Ph.D.Dr. Roger M. Perlmutter M.D.

Chief Operating OfficerMr. Michael A. Klobuchar

M.D.Dr. Roy D. Baynes FACP

Co-Founder & Member of Scientific Advisory BoardDr. Robert Tjian Ph.D.

Co-Founder & Member of Scientific Advisory BoardDr. Eric Betzig Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Column Group IV GP, LP	10% Owner	Sep 03 '26	Buy	11.56	89,200	1,031,045	89,200	Sep 08 04:33 PM
Column Group IV GP, LP	10% Owner	Feb 06 '26	Buy	18.00	2,117,760	38,119,680	4,312,139	Feb 09 09:19 PM
Foresite Capital Management IV	10% Owner	Feb 04 '26	Buy	18.00	55,555	999,990	1,318,983	Feb 06 07:37 PM
FRAZIER KENNETH C	Director	Feb 04 '26	Buy	18.00	111,111	1,999,998	111,111	Feb 06 06:33 PM
Wolfe Josh	Director	Feb 04 '26	Buy	18.00	277,776	4,999,968	138,888	Feb 06 06:27 PM
Lux Venture Partners V, LLC	10% Owner	Feb 04 '26	Buy	18.00	277,776	4,999,968	138,888	Feb 06 06:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EIKN

Eikon Therapeutics Inc

Upgrade your Finviz experience